In human colorectal cancer cell lines and murine colorectal cancer models CXD101 treatment has recently been shown by gene expression profiling to be associated with increased expression of genes associated with antigen processing and presentation, such as major histocompatibility antigen (MHC) class 1 and class 2 genes, as well as increased expression of genes involved pathways associated with natural killer cell mediated cytotoxicity [29]. The gene discussed is HLA-C; the disease is colorectal cancer.